Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense (NCT06993610)
A Phase 2, Multi-Center Study Consisting of a Randomized, Placebo-Controlled Period, Followed by an Open-Label Extension Period to Assess the Efficacy, Safety, and Tolerability of Tibulizumab in Adults With Hidradenitis Suppurativa
🩺 Plain-English Summary (8th-Grade Level)
The study is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of tibulizumab over 16 weeks (Period 1) in adults with hidradenitis suppurativa, followed by a 16-week open-label extension period in which all participants will receive tibulizumab (Period 2)
Who can join: Review the eligibility criteria below.
Location: Medical Dermatology Specialists (Phoenix) — Phoenix, Arizona
Age range: 18 Years to 70 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (61 Sites)
Showing the first 25 of 61 sites.
- Medical Dermatology Specialists (Phoenix) — Phoenix, Arizona
- First OC Dermatology Research, Inc. — Irvine, California
- Wallace Medical Group, Inc. — Los Angeles, California
- Northridge Clinical Trials — Northridge, California
- NorCal Clinical Research — Rocklin, California
- Florida Academic Dermatology Center — Coral Gables, Florida
- Skin Care Research, LLC — Hollywood, Florida
- Georgia Skin & Cancer Clinic — Savannah, Georgia
- Indiana University School of Medicine — Indianapolis, Indiana
- The Indiana Clinical Trials Center — Plainfield, Indiana
- Equity Medical LLC (Kentucky) — Bowling Green, Kentucky
- DS Research of Kentucky, LLC — Louisville, Kentucky
- DelRicht LLC — Baton Rouge, Louisiana
- Clinical Trials Management, LLC — Metairie, Louisiana
- Beth Israel Deaconess Medical Center — Boston, Massachusetts
- MediSearch Clinical Trials — Saint Joseph, Missouri
- Skin Cancer and Dermatology Institute — Reno, Nevada
- Equity Medical — New York, New York
- OptiSkin Medical — New York, New York
- Red River Research Partners — Fargo, North Dakota
- Optima Research — Boardman, Ohio
- ClinOhio Research Services — Columbus, Ohio
- Apex Clinical Research Center — Mayfield Heights, Ohio
- Best Skin Research LLC — Camp Hill, Pennsylvania
- Palmetto Clinical Trial Services — Anderson, South Carolina
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Hidradenitis Suppurativa (HS)
- A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa — Phoenix, Arizona
- Safety and Efficacy of Roflumilast Foam 0.3% in Adolescent and Adult Subjects With Hidradenitis Suppurativa — Missouri City, Texas
- A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial) — Irvine, California
- A Study to Evaluate the Efficacy of Botulinum Toxin in Patients With Hidradenitis Suppurativa — Worcester, Massachusetts
- ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa — Chapel Hill, North Carolina
Explore by condition: All Hidradenitis Suppurativa (HS) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.